Author: Mark Via
Chapter 1
BACKGROUND AND SCIENTIFIC OVERVIEW: THE FUNCTION AND CLASSIFICATION OF NUCLEAR RECEPTORS
1.1. The Functions and Mechanisms of Nuclear Receptors
1.2. Classifying Nuclear Receptors
Chapter 2
NUCLEAR RECEPTORS AND DISEASE: DEFINING PHARMACEUTICAL TARGETS
2.1. Overview
2.2. Thyroid Hormone Receptor-like Subfamily
TR
RAR
PPAR
Rev-erb and ROR
LXR and FXR
Vitamin D Receptor-like Group
2.3. Retinoid X Receptor-like Subfamily
HNF4
RXR
TR2 and TR4
TLX and PNR
COUP-TF
2.4. Estrogen Receptor-like Subfamily
ER and ERR
GR
MR
PR
AR
2.5. Nerve Growth Factor-IB-like Subfamily
2.6. Steroidogenic Factor-like Subfamily
SF1
LRH1
2.7. GCNF
2.8. Miscellaneous Receptors
DAX1
SHP
Chapter 3
DRUGS IN DEVELOPMENT: THE POTENTIAL IN MODULATING NUCLEAR RECEPTORS
3.1. Thyroid Hormone Receptor-like Subfamily
TR
Karo Bio
QuatRx Pharmaceuticals
Ligand Pharmaceuticals
VIA Pharmaceuticals
RAR
Roche
GlaxoSmithKline
Galderma Pharma
Allergan
Cipher Pharmaceuticals
Phosphagenics
CytRx/Zeria Pharmaceutical
Other RAR Modulators for Cancer
PPAR
Dr. Reddy’s Laboratories/Nordic Bioscience
Roche
InteKrin Therapeutics
Metabolex
Plexxikon
Kalypsys
DARA BioSciences
Cerenis Therapeutics/Nippon Chemiphar
SRI International
Omeros
Others
ROR
Orphagen Pharmaceuticals
LXR and FXR
Intercept Pharmaceutical
Exelixis/Bristol-Myers Squibb/Pfizer
Phenex Pharmaceuticals
Poxel
Pfizer/Karo Bio
Vitamin D Receptor-like Group
Chugai Pharmaceutical/Taisho Pharmaceutical
Cytochroma
Galderma Pharma/QuatRx Pharmaceuticals/Deltanoid Pharmaceuticals
Hybrigenics
Dermipsor
Johnson & Johnson
Marillion Pharmaceuticals
Bayer Schering Pharma
3.2. Retinoid X Receptor-like Subfamily
RXR
Basilea Pharmaceutica
3.3. Estrogen Receptor-like Subfamily
ER
Pfizer/Ligand Pharmaceuticals
QuatRx Pharmaceuticals
GTx/Ipsen
Adeona Pharmaceuticals
Pantarhei Bioscience
Ascend Therapeutics
Radius
Karo Bio/Merck
Repros Therapeutics
Bionovo
Chiesi Pharmaceuticals
Ausio Pharmaceuticals
Shenogen
PepTcell
Acadia Pharmaceuticals
Yeda Research and Development
Aragon Pharmaceuticals
GR
Corcept Therapeutics
CyDex Pharmaceuticals
OptiNose
Bayer Schering Pharma
CombinatoRx/Fovea Pharmaceuticals
Lithera
Foresight Biotherapeutics
EyeGate Pharmaceuticals
Otonomy
NicOx/Grupo Ferrer Internacional
Novagali Pharma
Karo Bio/Zydus Cadila
Isis Pharmaceuticals/Ortho-McNeil-Janssen Pharmaceuticals
Sun Pharma
Clavis Pharma
Others
MR
Exelixis/Daiichi Sankyo
Canopus BioPharma
PR
HRA Pharma/PregLem
Repros Therapeutics
Bayer Schering Pharma
NeuroScience Pharmaceuticals
Others
AR
Medivation/Astellas Pharma
Cosmo Pharmaceuticals
GTx/Merck
Harbor Biosciences
Tokai Pharmaceuticals
Ligand Pharmaceuticals
Pantarhei Bioscience
Radius
Adamis Pharmaceuticals/Colby Pharmaceuticals
Galapagos
Aragon Pharmaceuticals
Chugai Pharmaceutical
Enzon Pharmaceuticals/Santaris Pharma
Serometrix
Orion
3.4. Nerve Growth Factor-IB-like Subfamily
3.5. Steroidogenic Factor-like Subfamily
SF1
Orphagen Pharmaceuticals
LRH1
3.6. Miscellaneous Receptors
SHP
Pfizer
Chapter 4
OVERVIEW OF CLINICAL INDICATIONS AND NUCLEAR RECEPTORS
Chapter 5
CONCLUSIONS, DIRECTIONS AND IMPLICATIONS FOR THE MARKET